Four-specific antibodies! Baili Pharmaceuticals is once again in the study of anti-cancer drugs approved clinically.

According to the latest publicity from the Drug Review Center (CDE) of the State Drug Administration of China, the first class of new drug GNC-038 ivy antibody injections from Baili Pharmaceuticals has obtained a clinically implied license for the treatment of recurring or resuscitable non-Hodgkin's lymphoma (R/R NHL), recurring or resuscitated acute lymphoblastic leukemia (R/R ALL), recurring or metastatic solid tumors.
", according to the official website of Leigh Pharmaceuticals, is the world's first four-specific antibody successfully approved clinically.
this also makes after SI-B001 and SI-B003, The Hundred Pharmaceuticals another approved clinical anti-cancer drug in the study.
screenshot source: CDE official website Baili Pharmaceutical Group was founded in 1996, is a research and development, production and sales as one of the modern innovative pharmaceutical enterprises, the company's founder is Dr. Zhu Yi.
's official website shows that the company has established an innovative and efficient research and development system, including Baili Pharmaceuticals in China and its U.S. subsidiary Systimmune, focusing on malignant tumors, developing innovative antibody drugs with breakthrough efficacy, antibody-coupled drugs (ADCs), and children's drugs, anesthesia, severe illness, cardiovascular first aid drugs, and more.
GNC-038 is the first drug candidate to enter the clinic under the Guidance navigation and control platform, a "targeted immune" antibody for four specific structures that can target four antigens simultaneously and is clinically intended for the treatment of hematomas and solid tumors.
In addition to GNC-038, there are two dual-specific antibodies in the research and development pipeline of The Hundred Pharmaceuticals entered clinical research in China: one is SI-B001 dual-specific antibody injection, has been approved for the treatment of local late stage or metastatic endotrhea clinical research, including esophageal squamous cancer, pulmonary scale cancer, triple-yin breast cancer, head and neck squamous cancer, colorectal cancer; The other is si-B003 dual-specific antibody injections, which have been approved for clinical study as a treatment for localized advanced, relapsed or metastatic solid tumors, including renal cell carcinoma, colorectal cancer, melanoma, non-small cell lung cancer, urethra cancer, etc.
addition, there are still several drug candidates in the declaration and preclinical research stages on the B.I. Pharmaceuticals GNC platform.
-specific monoclonal antibody is one of the first widely used cancer immunotherapy, such as anti-PD-1/PD-L1 antibodies.
, dual-specific antibodies that can target both targets at the same time began to receive attention, such as Bite therapy Blincyto, which targets CD19 and CD3 receptors.
recent years, scientists have begun to study multisexual antibodies.
addition to the four-specific antibodies, a number of three-specific antibodies are being developed around the world.
: The Drug Review Center of the State Drug Administration of China. Retrieved Sep 3,2020, from the world's first four-specific antibody GNC-038 has been approved clinically in China.
retrieved Sep 02, 2020, from.